Psychemedics (NASDAQ: PMD) is one of 42 publicly-traded companies in the “Medical laboratories” industry, but how does it compare to its peers? We will compare Psychemedics to related companies based on the strength of its analyst recommendations, institutional ownership, risk, earnings, dividends, valuation and profitability.
This table compares Psychemedics and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a summary of recent ratings and recommmendations for Psychemedics and its peers, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
As a group, “Medical laboratories” companies have a potential upside of 49.79%. Given Psychemedics’ peers higher possible upside, analysts plainly believe Psychemedics has less favorable growth aspects than its peers.
Earnings and Valuation
This table compares Psychemedics and its peers revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Psychemedics||$21.36 million||-$3.86 million||-31.37|
|Psychemedics Competitors||$933.00 million||$35.52 million||-7.80|
Psychemedics’ peers have higher revenue and earnings than Psychemedics. Psychemedics is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
Risk and Volatility
Psychemedics has a beta of 0.75, meaning that its stock price is 25% less volatile than the S&P 500. Comparatively, Psychemedics’ peers have a beta of 0.80, meaning that their average stock price is 20% less volatile than the S&P 500.
Insider & Institutional Ownership
40.6% of Psychemedics shares are held by institutional investors. Comparatively, 51.7% of shares of all “Medical laboratories” companies are held by institutional investors. 13.3% of Psychemedics shares are held by insiders. Comparatively, 18.1% of shares of all “Medical laboratories” companies are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Psychemedics peers beat Psychemedics on 7 of the 10 factors compared.
Psychemedics Corp. engages in the provision of drug testing services through the analysis of hair samples. It specializes in a five panel drug testing process for cocaine, opioids, Phenyclidine, amphetamines, and marijuana. It offers workplace, school, and personal drug testing services. The company was founded by Werner Baumgartner and Annette Baumgartner on September 24, 1986 and is headquartered in Acton, MA.
Receive News & Ratings for Psychemedics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Psychemedics and related companies with MarketBeat.com's FREE daily email newsletter.